

**REPORT FROM OPIC PROJECT TEAM
TO INVESTMENT COMMITTEE**

SECTION I: NON-CONFIDENTIAL PROJECT INFORMATION

Host Country:	Poland
Name of Borrower:	OnkoMed Klinika Oncologii (“OnkoMed” or the “Company”)
U.S. Sponsor:	David B. Kaiser and Associates (the “U.S. Sponsor”)
Foreign Sponsors:	Swiss Invest Sp. zo.o. (“Swiss Invest”) and Medicover Holdings SA (with its affiliates, “Medicover,”) (together with the U.S. Sponsor, the “Sponsors”)
Project Description:	The development and operation of the first high-quality, private oncology care facility in Poland, which will include both diagnostic and treatment services. (the “Project”)
Total Project Cost:	\$24,000,000
Proposed OPIC Loan:	\$16,800,000
Developmental Effects:	In Warsaw, there is no private hospital or medical center that provides oncology-related diagnostic and therapeutic services and little funding is available from the public sector to improve this situation. This project will fill the need for a modern oncology center to provide standards of care in a cost-effective manner. This facility will be able to meet only a fraction of anticipated demand. In addition to this benefit, OnkoMed is expected to create over 100 technical and professional jobs in Poland and provide the local community with health and nutrition education.
Environment:	Health care projects are screened as Category B under OPIC’s environmental guidelines because impacts are site-specific and can readily be mitigated to acceptable levels.